Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...

The research was discussed Thursday at the San Antonio Breast Cancer Symposium. Every year, about 50,000 women in the U.S.

Two recent studies suggest that some early breast cancer patients may skip certain surgeries, potentially reducing treatment ...

Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they underwent ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...

Meta-analysis of three trials found that immediate breast surgery in women over 70 cut breast cancer death rates in half ...

Two recent studies explore options for early-stage breast cancer patients to reduce surgery. One suggests active monitoring ...

Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in partnership with the American Association for Cancer Research (AACR), hosts the 47th ...

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune ...

Additional new data will show how Myriad’s second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, ...

Tempus, a leader in artificial intelligence and precision medicine, today announced four abstracts were accepted for ...

Tissue Penetration: Consistent with the recently updated trial protocol, tissue Css levels were evaluated in addition to plasma Css levels. The 80 mg/day dose, in both treatment arms, achieved tissue ...